| Title |
Appropriateness of Oral Anticoagulants for the Long-Term Treatment of Atrial Fibrillation in Older People: Results of an Evidence-Based Review and International Consensus Validation Process (OAC-FORTA 2016)
|
|---|---|
| Published in |
Drugs & Aging, May 2017
|
| DOI | 10.1007/s40266-017-0466-6 |
| Pubmed ID | |
| Authors |
Martin Wehling, Ronan Collins, Victor M. Gil, Olivier Hanon, Roland Hardt, Martin Hoffmeister, Pedro Monteiro, Terence J. Quinn, Dieter Ropers, Giuseppe Sergi, Freek W. A. Verheugt |
| Abstract |
Age appropriateness of anticoagulants for stroke prevention in atrial fibrillation is uncertain. To review oral anticoagulants for the treatment of atrial fibrillation in older (age >65 years) people and to classify appropriate and inappropriate drugs based on efficacy, safety and tolerability using the Fit-fOR-The-Aged (FORTA) classification. We performed a structured comprehensive review of controlled clinical trials and summaries of individual product characteristics to assess study and total patient numbers, quality of major outcome data and data of geriatric relevance. The resulting evidence was discussed in a round table with an interdisciplinary panel of ten European experts. Decisions on age appropriateness were made using a Delphi process. For the eight drugs included, 380 citations were identified. The primary outcome results were reported in 32 clinical trials with explicit and relevant data on older people. Though over 24,000 patients aged >75/80 years were studied for warfarin, data on geriatric syndromes were rare (two studies reporting on frailty/falls/mental status) and missing for all other compounds. Apixaban was rated FORTA-A (highly beneficial). Other non-vitamin K antagonist oral anticoagulants (including low/high-intensity dabigatran and high-intensity edoxaban) and warfarin were assigned to FORTA-B (beneficial). Phenprocoumon, acenocoumarol and fluindione were rated FORTA-C (questionable), mainly reflecting the absence of data. All non-vitamin K antagonist oral anticoagulants and warfarin were classified as beneficial or very beneficial in older persons (FORTA-A or -B), underlining the overall positive assessment of the risk/benefit ratio for these drugs. For other vitamin-K antagonists regionally used in Europe, the lack of evidence should challenge current practice. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ireland | 2 | 29% |
| United Kingdom | 2 | 29% |
| Spain | 2 | 29% |
| Unknown | 1 | 14% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 57% |
| Practitioners (doctors, other healthcare professionals) | 2 | 29% |
| Scientists | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 128 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | <1% |
| Unknown | 127 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 19 | 15% |
| Student > Master | 18 | 14% |
| Student > Ph. D. Student | 13 | 10% |
| Student > Postgraduate | 10 | 8% |
| Student > Bachelor | 9 | 7% |
| Other | 19 | 15% |
| Unknown | 40 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 28% |
| Nursing and Health Professions | 15 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 9% |
| Biochemistry, Genetics and Molecular Biology | 3 | 2% |
| Economics, Econometrics and Finance | 2 | 2% |
| Other | 12 | 9% |
| Unknown | 49 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2018.
All research outputs
#2,209,986
of 22,971,207 outputs
Outputs from Drugs & Aging
#114
of 1,212 outputs
Outputs of similar age
#43,820
of 310,780 outputs
Outputs of similar age from Drugs & Aging
#2
of 19 outputs
Altmetric has tracked 22,971,207 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,212 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,780 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.